Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Website URL
Similar Companies1000
NAKI Therapeutics
NAKI Therapeutics develops immunotherapy to safely kill cancer cells using natural killer cells.
Sector
Subsector
Keywords
Location
total rounds
Cytovia Therapeutics
Cytovia Therapeutics develops groundbreaking cancer immunotherapies, addressing unmet medical needs in cancer prevention.
Sector
Subsector
Keywords
Location
Exacis Biotherapeutics
Exacis is a development-stage immuno-oncology company focused on curing cancer by harnessing the human immune system.
Sector
Subsector
Keywords
Location
Mogrify
Mogrify is a biopharmaceutical company that has developed a direct cellular reprogramming platform.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.03.2024. Their latest investor Janus Henderson Investors. Their latest round Post-IPO Equity
Samsara BioCapital
Samsara BioCapital is a Palo Alto-based venture capital firm specializing in life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors17
Number of lead investors
Number of investors
Janus Henderson Investors
Janus Henderson Investors is a leading global active asset manager that helps clients achieve their long-term financial goals.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Commodore Capital
Commodore Capital partners with biopharmaceutical companies to develop medical products that improve patients' lives.
Sector
Subsector
Keywords
Location
count Of Investments
Boxer Capital
Boxer Capital supports biotech public companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders1
Paul Hastings
Paul Hastings was appointed Chief Executive Officer of Nkarta in February 2018. Mr. Hastings was recently the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.
organization founded
Paul Hastings
Employee Profiles13
Activity
Recent News2
The graph reveals the ratio (%) of positive news articles in a chosen time range